Laparoscopically assisted percutaneous endoscopic gastrostomy

G. Croaker,A. Najmaldin

DOI: https://doi.org/10.1007/BF01349979

1997-03-21

Abstract:

What problem does this paper attempt to address?

YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression

Xuan Li,Hongguang Zhong,Qianqian Shi,Ruiwen Ruan,Chunye Huang,Qin Wen,Shaocheng Zeng,Yang Xia,Qinru Zeng,Jianping Xiong,Shanshan Wang,Jun Chen,Wan Lei,Jun Deng

DOI: https://doi.org/10.1007/s00018-024-05178-3

IF: 8

2024-03-19

Cellular and Molecular Life Sciences

Abstract:Hippo-Yes-associated protein 1 (YAP1) plays an important role in gastric cancer (GC) progression; however, its regulatory network remains unclear. In this study, we identified Copine III ( CPNE3 ) was identified as a novel direct target gene regulated by the YAP1/TEADs transcription factor complex. The downregulation of CPNE3 inhibited proliferation and invasion, and increased the chemosensitivity of GC cells, whereas the overexpression of CPNE3 had the opposite biological effects. Mechanistically, CPNE3 binds to the YAP1 protein in the cytoplasm, inhibiting YAP1 ubiquitination and degradation mediated by the E3 ubiquitination ligase β-transducin repeat-containing protein (β-TRCP). Thereby activating the transcription of YAP1 downstream target genes, which creates a positive feedback cycle to facilitate GC progression. Immunohistochemical analysis demonstrated significant upregulation of CPNE3 in GC tissues. Survival and Cox regression analyses indicated that high CPNE3 expression was an independent prognostic marker for GC. This study elucidated the pivotal involvement of an aberrantly activated CPNE3/YAP1 positive feedback loop in the malignant progression of GC, thereby uncovering novel prognostic factors and therapeutic targets in GC.

cell biology,biochemistry & molecular biology
YAP induces FAK phosphorylation to inhibit gastric cancer cell proliferation via upregulation of HMGB1

Yunhe Jiang,Lifu Fu,Bin Liu,Fan Li

DOI: https://doi.org/10.1016/j.ijbiomac.2024.130037

IF: 8.2

2024-03-01

International Journal of Biological Macromolecules

Abstract:Yes associated protein (YAP) is the main effector protein in the Hippo pathway, regulating cell growth by binding to transcription factors in the nucleus. However, the mechanisms by which YAP regulates the development and progression of gastric cancer (GC) remain largely unknown. In this study, bioinformatics analysis determined that YAP was significantly upregulated in GC and associated with poor prognosis. In addition, YAP deletion inhibits proliferation and migration of GC cells in vitro, while overexpression of YAP has the opposite effect. Mechanistically, overexpression of YAP induced FAK phosphorylation in gastric cancer cells, whereas knockdown of YAP had the opposite effect. Importantly, translocation expressed mutant plasmid YAP-S94A (YAP1 mutant without TEAD binding site) did not significantly change the level of FAK phosphorylation. Furthermore, Verteporfin (a small molecule inhibitor of YAP) interrupted the YAP-TEAD interaction and inhibited FAK phosphorylation, confirming that YAP can induce FAK phosphorylation in a TEAD-dependent manner. In addition, the silencing of FAK or the use of FAK inhibitors inhibited the aggregation of YAP proteins in the nucleus, forming a FAK-YAP positive feedback loop. Finally, we identify the FAK upstream gene, HMGB1, as a direct transcriptional target of YAP-TEAD. Silencing HMGB1 reversed YAP-induced FAK activation as well as cell proliferation and migration. Collectively, our results reveal a new signalling axis, YAP/HMGB1/FAK, in the regulation of cell proliferation and migration, and provide new insights into the crosstalk between Hippo signalling and cell proliferation.

polymer science,biochemistry & molecular biology,chemistry, applied
Significant association of YAP1 and HSPC111 proteins with poor prognosis in Chinese gastric cancer patients

Shanshan Huang,Lingling Zhu,Yuan Cao,Li Li,Yongtao Xie,Jun Deng,Jianping Xiong

DOI: https://doi.org/10.18632/oncotarget.17932

2017-05-17

Oncotarget

Abstract:Hippo-YAP1 is a tumor-suppressor signaling pathway that inhibits cell proliferation and accelerates apoptosis. However, the role of YAP1 in gastric cancer (GC) is still in dispute. Ribosomal biogenesis is closely correlated with human malignancies. HBV pre-S2 trans-regulated protein 3 (HSPC111) is a portion of an RNA-dependent complex and plays a crucial role in ribosome biosynthesis. Nevertheless, little is known about the expression and function of this factor in GC. In the present study, we evaluated the significance of YAP1 together with HSPC111 in gastric cancer. According to The Cancer Genome Atlas database, high YAP1 mRNA expression was significantly associated with poor prognosis of GC patients, and dramatically increased mRNA levels of HSPC111 are observed in GC tissues. Consistent with these findings, we detected increased expression of both YAP1 and HSPC111 in GC cell lines and clinical samples. Notably, nuclear expression of YAP1 was positively correlated with clinical stage (<i>P</i> = 0.041), tumor size (<i>P</i> = 0.023), and lymph node metastasis (<i>P</i> = 0.007), while HSPC111 expression was correlated with lymph node metastasis (<i>P</i> = 0.014). Our analyses also detected a correlation between HSPC111 expression and nuclear and cytoplasmic YAP1 in clinical samples (nuclear: <i>r</i> = 0.2615, <i>P</i> = 0.004; cytoplasm: <i>r</i> = -0.3721, <i>P</i> < 0.001) and cell lines. Finally, we showed that patients who were HSPC111- and nuclear YAP1-positive were associated with the worst prognosis (34.5 ± 4.8 months, <i>p</i> = 0.001), and that nuclear expression of YAP1 might act as an independent prognostic factor for GC patients.
YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes

Haoyuan Chen,Yangyang Shang,Xia Li,Rongquan Wang

DOI: https://doi.org/10.1080/15384101.2024.2309017

2024-01-25

Cell Cycle

Abstract:Yes-associated protein1 (YAP1), a downstream effector of the Hippo pathway, is over-expressed in several types of malignancies. We analyzed retrospectively the TCGA database using 447 colorectal cancer (CRC) samples to determine the correlation between YAP1 expression level and CRC patient prognosis. YAP1-enforced expressed CRC cell lines were constructed using the lentivirus particles containing a YAP1 insert. YAP1 was highly expressed in CRC cancerous tissues and is associated with distant metastasis of CRC patients. Kaplan – Meier analysis indicated that CRC patients with a higher YAP1 expression group ( n = 104) had worse disease-free survival (DFS) and overall survival (OS) than lower YAP1 expression group ( n = 343) ( p = 0.008 and p = 0.022). Univariate and multivariate analysis indicated that the elevated YAP1 expression predicted the aggressive phenotype and was an independent indicator for OS and DFS of CRC patients. YAP1 over-expression in CRC cells enhanced their migration and invasion significantly which can be reversed by AXL, CTGF, or CYR61 interference. The study suggested that YAP1 affected the prognosis of CRC patients and controlled the abilities of invasion and migration of CRC cells via its target genes AXL, CTGF, and CYR61.

cell biology
Gli1 Interacts with YAP1 to Promote Tumorigenesis in Esophageal Squamous Cell Carcinoma.

Chongchong Wang,Li Cheng,Shasha Song,Shan Wu,Guoping Sun

DOI: https://doi.org/10.1002/jcp.29477

2020-01-01

Journal of Cellular Physiology

Abstract:Esophageal squamous cell carcinoma (ESCC) is the predominant esophageal cancer type in China. The aberrant activation of glioma‐associated oncogene homolog1 (Gli1), a key factor in Hedgehog (Hh) signaling pathway, has been found in esophageal carcinoma. Moreover, Yes‐associated protein 1 (YAP1), the major mediator of Hippo signaling pathway, has been linked to esophageal carcinoma progression. However, the precise roles and the underlying mechanism of both Gli1 and YAP1 in ESCC are unclear. Here, we found that Gli1 and YAP1 are overexpressed in ESCC and are associated with poor prognosis. In addition, we confirmed that knockdown of Gli1 or YAP1 suppresses ESCC cell growth, migration, and invasion in ESCC TE1 and EC109 cells. Significantly, Gli1 interacts with YAP1 in ESCC cells. Both Gli1 and YAP1 proteins are closely correlated with each other in human ESCC samples. Mechanistically, Gli1 upregulates YAP1 in a LATS1‐independent manner. Conversely, YAP1 induces Gli1 by regulating phosphoinositide 3‐kinase (PI3K)/AKT signaling pathway. Most importantly, we demonstrated that the interaction between Gli1 and YAP1 promotes ESCC tumor growth in vitro and in vivo. Our findings established a novel signaling mechanism by which the interaction between Gli1 and YAP1 promotes ESCC cell growth. This signaling regulation of the tumorigenesis provides a new therapeutic strategy for highly lethal ESCC.
Yes-associated Protein 1 Promotes Papillary Thyroid Cancer Cell Proliferation by Activating the ERK/MAPK Signaling Pathway

Tian Liao,Duo Wen,Ben Ma,Jia-Qian Hu,Ning Qu,Rong-Liang Shi,Liang Liu,Qing Guan,Duan-Shu Li,Qing-Hai Ji

DOI: https://doi.org/10.18632/oncotarget.14319

2016-01-01

Oncotarget

Abstract:Yes-associated protein 1 (YAP1) stimulates cell proliferation, epithelial-tomesenchymal transition, invasion and metastasis in several cancers. Here, we investigated the involvement of YAP1 in papillary thyroid carcinoma (PTC) by assessing YAP1 mRNA and protein levels in PTC tissues and matched normal thyroid epithelial tissues from 50 patients. YAP1 mRNA and protein levels were higher in PTC tumor tissues than in control tissues, and correlated positively with the levels of proliferation-related genes (KI67 and c-MYC). We also used lentiviral vectors to overexpress or silence YAP1 expression in the K1 PTC cell line so that we could investigate the effects of YAP1 on cancer cell proliferation. YAP1 overexpression enhanced PTC cell proliferation by activating ERK1/2 and AKT, and these effects were impaired by treating the cells with the MEK inhibitor U0126 or the AKT inhibitor GSK690693. Finally, YAP1 overexpression dramatically induced growth of tumors from PTC cells in a xenograft mouse model. These results suggest that YAP1 enhances cell proliferation in PTC, and thus may be a promising target in the treatment of PTC.
EphA2-to-YAP pathway drives gastric cancer growth and therapy resistance

Changhao Huang,Weijie Yuan,Chen Lai,Shangwei Zhong,Chen Yang,Ran Wang,Linfeng Mao,Zihua Chen,Zhikang Chen

DOI: https://doi.org/10.1002/ijc.32609

2020-01-01

International Journal of Cancer

Abstract:Yes-associated protein (YAP) is a transcriptional coactivator that promotes cell proliferation, stem cell maintenance and tissue homeostasis. The YAP activity is primarily regulated through an inhibitory phosphorylation by the serine/threonine kinases of Hippo pathway. Here, we show that receptor tyrosine kinase (RTK) erythropoietin-producing hepatocellular receptor A2 (EphA2) interacts with and phosphorylates YAP protein, leading to stabilization, nuclear translocation and activation of YAP in gastric cancer (GC) cells. EphA2 induces chemotherapy-resistance by increasing YAP stability and nuclear YAP protein. Knockdown of YAP blocks EphA2-induced tumor growth in GC xenograft mouse models. Importantly, the coactivation of EphA2 and YAP is manifested in clinical human GC, and is related to GC recurrence. Thus, our results establish a novel EphA2-to-YAP pathway that drives GC growth, progression and therapy-resistance, targeting this pathway would be an efficient way for the treatment of GC, particularly chemotherapy-resistant GC.
Multi-day Adaptation and Savings in Manual and Locomotor Tasks

Marit F. L. Ruitenberg,Y. D. Dios,N. Gadd,S. J. Wood,P. Reuter-Lorenz,I. Kofman,J. Bloomberg,A. Mulavara,R. Seidler

DOI: https://doi.org/10.1080/00222895.2017.1371110

2018-09-01

Journal of Motor Behavior

Abstract:ABSTRACT Using an individual differences approach, we evaluated whether manual and locomotor adaptation are associated in terms of adaptation and savings across days, and whether they rely on shared underlying mechanisms involving visuospatial working memory or visual field dependence. Participants performed a manual and a locomotor adaptation task during 4 separate test sessions over a 3-month period. Reliable adaptation and savings were observed for both tasks. It was further found that higher visuospatial working memory performance and lower visual field dependence scores were associated with faster learning in the manual and locomotor tasks, respectively. Moreover, adaptation rates were correlated between the 2 tasks in the final test session, suggesting that people may gradually be learning something generalizable about the adaptation process.
Yes-Associated Protein 1 (Yap) In The Growth And Tumorigenesis Of Ovarian Granulosa Cells.

Xiangmin Lv,Chunbo He,Guohua Hua,Jixin Dong,John S. Davis,Cheng Wang

DOI: https://doi.org/10.1158/1557-3265.OVCA15-A37

IF: 13.801

2016-01-01

Clinical Cancer Research

Abstract:Abstract Ovarian granulosa cells are essential for successful follicle development. Dysregulation of granulosa cell proliferation and differentiation may lead to impairment of female fertility or development of ovarian tumors. Although studies indicate that the Hippo signaling pathway plays critical roles in both development and tumorigenesis of several organs, its role in ovarian physiology and pathology remains largely unknown. The present study aims to investigate the role of YAP in ovarian granulosa cell proliferation, differentiation and transformation. Immunohistochemical analyses showed that the active form of YAP (nuclear YAP) was highly expressed in proliferative granulosa cells, whereas the inactive form of YAP (cytoplasmic YAP) was detected mainly in terminally-differentiated luteal cells, indicating that YAP may be involved in proliferation and differentiation of ovarian granulosa cells. Knockdown of YAP or pharmacological inhibition of YAP activity in human granulosa cells suppressed cell growth and reduced cell survival in both traditional 2D cell culture system and a novel 3D hanging-drop culture system, suggesting that YAP is essential for the growth and survival of human granulosa cells. In addition, ectopic expression of wild-type or constitutively active YAP impaired gonadotropin-induced differentiation of granulosa cells and stimulated the rapid growth and transformation of granulosa cells, findings which were reflected by increased colony formation in soft agar assay and growth of tumors in a xenograft mouse model. Injection of verteporfin (a selective antagonist of YAP) into female CD1 mice inhibited granulosa cell growth, induced GC apoptosis, and disrupted mouse ovarian follicle development, leading to severe subfertility. Consistently, mice with ovarian granulosa cell-specific expression of constitutively active YAP demonstrated disruption of granulosa cell differentiation and failure of ovarian follicle development. In conclusion, our studies demonstrate that homeostatic YAP expression and activation are essential for ovarian granulosa cell proliferation, differentiation and survival. YAP is a novel therapeutic target for treatment of ovarian diseases associated with granulosa cell dysregulation. Citation Format: Xiangmin Lv, Chunbo He, Guohua Hua, Jixin Dong, John S. Davis, Cheng Wang. Yes-associated protein 1 (YAP) in the growth and tumorigenesis of ovarian granulosa cells. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A37.
LncRNA PVT1 Promotes Cell Proliferation, Invasion, and Migration and Inhibits Cell Apoptosis by Phosphorylating YAP

Kaiyue Ji,Qi Zhang,Wen Song,Tao Mao,Jing Guo,Congcong Min,Cuiping Zhang,Zibin Tian,Xiaoyu Li

DOI: https://doi.org/10.1155/2022/5332129

2022-05-27

Canadian Journal of Gastroenterology and Hepatology

Abstract:Gastric cancer (GC) as a serious global health problem is a threat to human longevity. Plasmacytoma variant translocation 1 (PVT1) participates in the formation and progression of various cancers, including GC. The aim of this study is to investigate the mechanism underlying the functions of PVT1 and explore a novel target for the diagnosis and treatment of GC. Analysis of the TCGA dataset using the R software identified that the lncRNA PVT1 was greatly upregulated in GC tissues. Twenty pairs of GC and adjacent normal tissues were acquired from patients with GC, and the expression of PVT1 was evaluated using RT-qPCR. Furthermore, PVT1 expression was knocked down in GC cells using siRNA, and the GC cells were divided into control, negative control (NC), and siRNA groups. Cell proliferation ability was analyzed using Cell Counting Kit-8 (CCK8) and colony formation assays, whereas cell migration and invasion ability were investigated through wound healing and Transwell assays. Moreover, Western blotting was used to analyze the expression of Yes-associated protein (YAP) and epithelial-to-mesenchymal transition (EMT) proteins. We also found that PVT1 and YAP expressions were upregulated in the GC tissues compared with those in the adjacent nontumor tissues. Knockdown of PVT1 was found to inhibit the proliferation, invasion, and migration and promote apoptosis of GC cells. Furthermore, knockdown of PVT1 downregulated YAP and promoted phosphorylation of YAP, suggesting that PVT1 exerts actions on GC cells by targeting YAP and inhibits cell apoptosis in vitro. The EMT process was also inhibited by the knockdown of PVT1. In summary, lncRNA PVT1 facilitated cell proliferation, invasion, and migration and suppressed cell apoptosis by targeting YAP. This study suggests that the expressions of PVT1 and YAP could be used for the early detection of GC and the occurrence and development of GC could be inhibited by interfering the interaction of PVT1 and YAP, which will provide new insights for the diagnosis, treatment, and prognosis of GC.

gastroenterology & hepatology
USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer

Zhen Liu,Junhe Li,Yun Ding,Mei Ma,Jun Chen,Wan Lei,Li Li,Yangyang Yao,Xin Yu,Min Zhong,Quan Liao,Weidan Fang,Linwei Fan,Chunye Huang,Hongguang Zhong,Qin Wen,Zi Fang,Jingyi Chen,Shanshan Huang,Jianpin Xiong,Xiaojun Xiang,Jun Deng

DOI: https://doi.org/10.1038/s41388-022-02267-0

IF: 8.756

2022-03-22

Oncogene

Abstract:The importance of the Hippo-Yes-associated protein 1 (YAP1) pathway in gastric carcinogenesis and metastasis has attracted considerable research attention; however, the regulatory network of YAP1 in gastric cancer (GC) is not completely understood. In this study, ubiquitin-specific peptidase 49 (USP49) was identified as a novel deubiquitinase of YAP1, knockdown of USP49 inhibited the proliferation, metastasis, chemoresistance, and peritoneal metastasis of GC cells. Overexpression of USP49 showed opposing biological effects. Moreover, USP49 was transcriptionally activated by the YAP1/TEAD4 complex, which formed a positive feedback loop with YAP1 to promote the malignant progression of GC cells. Finally, we collected tissue samples and clinical follow-up information from 482 GC patients. The results showed that USP49 expression was high in GC cells and positively correlated with the expression of YAP1 and its target genes, connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61). Survival and Cox regression analysis showed that high USP49 expression was associated with poor prognosis and was an independent prognostic factor. Moreover, patients with high USP49 and YAP1 expression had extremely short overall survival. The findings of this study reveal that the aberrant activation of the USP49/YAP1 positive feedback loop plays a critical role in the malignant progression of GC, thus providing potential novel prognostic factors and therapeutic targets for GC.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Expression of Yes-associated protein in gastric adenocarcinoma and its clinical significance

Bo YU,Hui CHEN,Wei WANG,Yulei YIN,Li XIAO,Hua WANG,Yao LI,Yan CHEN

DOI: https://doi.org/10.11877/j.issn.1672-1535.2017.15.04.24

2017-01-01

Abstract:Objective To explore the expression of YAP protein and its relation to clinicopathological factors and prognosis in patients with gastric adenocarcinoma. Method The expression of YAP protein in gastric adenocarcinoma tissues was measured with immunohistochemical method, and its relation to clinicopathological factors and prognosis in patients with gastric adenocarcinoma was analyzed using Kaplan-Meier univariate analysis and multivariate analysis with Cox proportional hazard model. Result In gastric adenocarcinoma issues, the positive expression of YAP protein was found in the cytoplasm of 31.6%samples and in the nuclei of 22.4%samples, both significantly higher than those in nor-mal gastric mucosa (1.0% and 0.0%, respectively) (P<0.01). The positive expression of YAP protein in cytoplasm was positively correlated with the positive expression in nuclei (Sperman correlation coefficient=0.5818, P<0.0001). Results of Kaplan-Meier univariate analysis showed that the 5 year survival rate of patients with positive YAP expression in nu-clei was lower than that of patients with negative results (P<0.05). The results of multivariate analysis using Cox propor-tional hazard model showed that the expression of YAP protein could not be used as an independent predictor of progno-sis in patients with gastric adenocarcinoma (P>0.05). Conclusion Some gastric adenocarcinoma issues have high expres-sion of YAP protein, the nuclear expression of YAP protein and the poor prognosis of gastric adenocarcinoma can be used as an early diagnostic marker for this disease.
Overexpressed MAGP1 is Associated with a Poor Prognosis and Promotes Cell Migration and Invasion in Gastric Cancer

Mengjie Wu,Yongfeng Ding,Xiaoxia Jiang,Yanyan Chen,Nan Wu,Linrong Li,Haiyong Wang,Yingying Huang,Nong Xu,Lisong Teng

DOI: https://doi.org/10.3389/fonc.2019.01544

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Gastric cancer (GC) is a frequently occurring malignancy with high mortality rates. However, the underlying mechanism of GC progression is not very clear. The aim of this study is to reveal the inherent molecular mechanism and develop potential therapeutic targets for advanced GC. The microfibril-associated glycoprotein 1 (MAGP1), identified as a potential oncogene, was found upregulated in GC tissues and high MAGP1 expression was associated with aggressive clinicopathological features. Furthermore, the multivariate Cox regression analysis showed that high MAGP1 expression was an independent predictor of poor prognosis (HR = 2.37, 1.07-5.24; P = 0.033). Mechanistically, MAGP1 promoted the migration and invasiveness of GC cells. In addition, the genes co-expressed with MAGP1 were primarily enriched in focal adhesion and PI3K-Akt pathways. MAGP1 overexpression enhanced the phosphorylation of FAK, AKT, and mTOR, whereas its knockdown also inactivated these factors. Furthermore, the AKT inhibitor suppressed the phosphorylation of AKT, FAK, and mTOR in recMAGP1-treated AGS cells, as well as their migration and invasion capacities. Finally, correlation analysis indicated that MAGP1 is involved in AKT signaling in GC, and is clinically relevant. Taken together, MAGP1 is a promising prognostic marker and potential therapeutic target for advanced GC.
YAP is a Critical Oncogene in Human Cholangiocarcinoma

Tiemin Pei,Yuejin Li,Jiabei Wang,Huanlai Wang,Yingjian Liang,Huawen Shi,Boshi Sun,Dalong Yin,Jing Sun,Ruipeng Song,Shangha Pan,Yu Sun,Hongchi Jiang,Tongsen Zheng,Lianxin Liu

DOI: https://doi.org/10.18632/oncotarget.4043

2015-01-01

Oncotarget

Abstract:Yes-associated protein (YAP), a transcriptional co-activator, has important regulatory roles in cell signaling and is dysregulated in a number of cancers. However, the role of YAP in cholangiocarcinoma (CCA) progression remains unclear. Here, we demonstrated that YAP was overexpressed in CCA cells and human specimens. High levels of nuclear YAP (nYAP) correlated with histological differentiation, TNM stage, metastasis and poor prognosis in CCA. Silencing YAP increased tumor sensitivity to chemotherapy and inhibited CCA tumorigenesis and metastasis both in vivo and in vitro. YAP overexpression in vivo and in vitro promoted CCA tumorigenesis and metastasis. Additionally, we found that YAP induced epithelial-mesenchymal transition (EMT) and formed a regulatory circuit with miR-29c, IGF1, AKT and gankyrin to promote the progression of CCA. Results of CCA tissue microarray showed positive correlations between nYAP and gankyrin or p-AKT expression. Combination of nYAP and gankyrin or p-AKT exhibited improved prognostic accuracy for CCA patients. In conclusion, YAP promotes carcinogenesis and metastasis by up-regulating gankyrin through activation of the AKT pathway.
Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy

Hongzhu Yan,Chengmin Qiu,Weiwei Sun,Minmin Gu,Feng Xiao,Jue Zou,Li Zhang

DOI: https://doi.org/10.3892/or.2018.6252

2018-02-07

Oncology Reports

Abstract:Gastric cancer is the fifth most common cancer worldwide and Hippo-Yap is the novel signaling pathway which plays an important role in gastric cancer tumor development and progression. However, little insight is available to date regarding the specific role of Yes-associated protein (Yap) in gastric cancer. In the present study, we identified the mechanism through which Yap sustains gastric cancer viability and migration. Yap was greatly upregulated in gastric cancer cells and its expression promoted cellular migration and survival. Functional studies found that knockdown of Yap reduced the mitophagy activity, which subsequently caused mitochondrial apoptosis and cellular oxidative stress. The latter impaired adhesive protein expression, alleviated F-actin expression, blunted lamellipodium formation, leading to inhibition of cancer cell motility. Mechanistically, Yap preserved Sirtuin 1 (SIRT1) activity which manipulated mitofusin 2 (Mfn2) expression and subsequent mitophagy. Loss of Yap reduced SIRT1 expression and inhibited Mfn2-mediated mitophagy. Collectively, our results identified Hippo-Yap as a tumor promoter in gastric cancer that was mediated via activation of the SIRT1/Mfn2/mitophagy axis, with potential applications to gastric cancer therapy involving cancer survival and migration.

oncology
[Subgroup analysis results of platelet inhibition trial in acute coronary syndrome patients (PLATO) who underwent intervention or medical treatment].

E. Aksakal

2013-04-01

Abstract:Antiplatelet agents are among the most important drug classes in reducing mortality in patients with acute coronary syndromes (ACS). Ticagrelor is the first reversible and direct acting P2Y(12) receptor inhibitor with an earlier onset of action compared to clopidogrel. The PLATO study (Platelet Inhibition and Patient Outcomes) with ticagrelor was conducted with a design providing consistency with the current clinical practice, including all forms of ACS and a wide spectrum of treatment options in 18624 patients from 862 centers in 43 countries. Of these patients, 13408 underwent interventional procedures (ticagrelor/clopidogrel; 6732/6676) (PLATO-INVASIVE). As reported by the investigator, non-invasive treatment strategy was planned for 5216 patients (ticagrelor/clopidogrel; 2601/2615). However, 2040 patients in this group received interventional treatment during the follow-up (PLATO-NON-INVASIVE/MEDICAL TREATMENT). 1261 patients requiring surgical treatment underwent coronary artery bypass grafting (CABG) within 7 days after the discontinuation of study treatment (ticagrelor/clopidogrel; 632/629) (PLATO-CABG). The results of these three subgroups were consistent with the main PLATO study results, demonstrating that ticagrelor reduced the primary (cardiovascular death, myocardial Infarction and stroke) and secondary composite endpoints without increasing bleeding compared with clopidogrel. Ticagrelor fulfills an important unmet need regarding antiplatelet effectiveness in patients with ACS. This review evaluates the INVASIVE and MEDICAL subgroup studies of the PLATO study.
PKP2 induced by YAP/TEAD4 promotes malignant progression of gastric cancer

Yunyun Liu,Yi Lu,Yuanxin Xing,Wenshuai Zhu,Duanrui Liu,Xiaoli Ma,Yunshan Wang,Yanfei Jia

DOI: https://doi.org/10.1002/mc.23751

2024-05-29

Molecular Carcinogenesis

Abstract:Gastric cancer (GC) exhibits significant heterogeneity and its prognosis remains dismal. Therefore, it is essential to investigate new approaches for diagnosing and treating GC. Desmosome proteins are crucial for the advancement and growth of cancer. Plakophilin‐2 (PKP2), a member of the desmosome protein family, frequently exhibits aberrant expression and is strongly associated with many tumor types' progression. In this study, we found upregulation of PKP2 in GC. Further correlation analysis showed a notable association between increased PKP2 expression and both tumor stage and poor prognosis in individuals diagnosed with gastric adenocarcinoma. In addition, our research revealed that the Yes‐associated protein1 (YAP1)/TEAD4 complex could stimulate the transcriptional expression of PKP2 in GC. Elevated PKP2 levels facilitate activation of the AKT/mammalian target of rapamycin signaling pathway, thereby promoting the malignant progression of GC. By constructing a mouse model, we ultimately validated the molecular mechanism and function of PKP2 in GC. Taken together, these discoveries suggest that PKP2, as a direct gene target of YAP/TEAD4 regulation, has the potential to be used as an indication of GC progression and prognosis. PKP2 is expected to be a promising therapeutic target for GC.

oncology,biochemistry & molecular biology
m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1

Wenjie Zhou,Qingying Xian,Qi Wang,Chen Wu,Haijiao Yan,Xiaodong Li,Lu Lu,Changping Wu,Danxia Zhu,Xiaoli Xu,Jun Wu

DOI: https://doi.org/10.1155/2021/8875424

IF: 4.501

2021-08-04

Journal of Oncology

Abstract:Gastric cancer is the most common gastrointestinal tumor with an increasing incidence. Furthermore, advanced gastric cancer is more common, but the mechanism underlying the proliferation and metastasis of gastric cancer has not been thoroughly explored. N6-methyladenosine (m6A) methyltransferase 3 (METTL3) may be involved in the proliferation and metastasis of gastric cancer. Therefore, Yes-associated protein 1 (YAP1) in the Hippo pathway was selected as the target, and the relationship between METTL3 and the proliferation and metastasis of gastric cancer was proved through a series of experiments. This research showed that the expression of m6A and METTL3 was upregulated in human gastric cancer tissues and gastric cancer cell lines. After lentiviral transfection, METTL3 silencing in AGS (human gastric adenocarcinoma cell line AGS) and MKN-45 (human gastric cancer cell line MKN-45) gastric cancer cell lines directly inhibited the proliferation, aggressiveness, and migration of gastric cancer cells. Mechanically, the inhibition of the YAP1-TEAD signaling pathway by peptide 17 reduces m6A methylation and the total mRNA level of YAP1. It also eliminates the promoting effect of METTL3 on the proliferation and migration of gastric cancer cells. In turn, the overexpression of YAP1 eliminates the inhibitory effect of METTL3 silencing on the proliferation, migration, and invasion of gastric cancer cells. This article proved that m6A methyltransferase METTL3 promoted the proliferation and migration of gastric cancer cells through the m6A modification of YAP1.

oncology
YAP Regulates Cell Proliferation, Migration, and Steroidogenesis in Adult Granulosa Cell Tumors.

David Fu,Xiangmin Lv,Guohua Hua,Chunbo He,Jixin Dong,Subodh M Lele,David Wan-Cheng Li,Qiongli Zhai,John S Davis,Cheng Wang

DOI: https://doi.org/10.1530/erc-13-0339

2014-01-01

Abstract:The Hippo signaling pathway has been implicated as a conserved regulator of organ size in both Drosophila and mammals. Yes-associated protein (YAP), the central component of the Hippo signaling cascade, functions as an oncogene in several malignancies. Ovarian granulosa cell tumors (GCT) are characterized by enlargement of the ovary, excess production of estrogen, a high frequency of recurrence, and the potential for malignancy and metastasis. Whether the Hippo pathway plays a role in the pathogenesis of GCT is unknown. This study was conducted to examine the expression of YAP in human adult GCTs and to determine the role of YAP in the proliferation and steroidogenesis of GCT cells. Compared with age-matched normal human ovaries, GCT tissues exhibited higher levels of YAP expression. YAP protein was predominantly expressed in the nucleus of tumor cells, whereas the non-tumor ovarian stromal cells expressed very low levels of YAP. YAP was also expressed in cultured primary human granulosa cells and in KGN and COV434 GCT cell lines. siRNA-mediated knockdown of YAP in KGN cells resulted in a significant reduction in cell proliferation (P<0.001). Conversely, overexpression of wild type YAP or a constitutively active YAP (YAP1) mutant resulted in a significant increase in KGN cell proliferation and migration. Moreover, YAP knockdown reduced FSH-induced aromatase (CYP19A1) protein expression and estrogen production in KGN cells. These results demonstrate that YAP plays an important role in the regulation of GCT cell proliferation, migration, and steroidogenesis. Targeting the Hippo/YAP pathway may provide a novel therapeutic approach for GCT.
Nonreceptor tyrosine phosphatase 14 promotes proliferation and migration through regulating phosphorylation of YAP of Hippo signaling pathway in gastric cancer cells

Xu Han,Tong Sun,Jia Hong,Rongrong Wei,Yingzi Dong,Di Huang,Jie Chen,Xiyun Ren,Haibo Zhou,Wenjing Tian,Yunhe Jia

DOI: https://doi.org/10.1002/jcb.29038

2019-06-06

Journal of Cellular Biochemistry

Abstract:<h3> Background</h3><p>The Hippo signaling pathway is associated with cell proliferation and organ size, and its transcriptional coactivator Yes‐associated protein (YAP), emerges as a crucial oncoprotein in multiple cancers. It was increasingly recognized that nonreceptor tyrosine phosphatase 14 (PTPN14) was relevant to the cell membrane and cytoskeleton, and had a critical effect on cell adhesion, growth, and actin cytoskeleton organization. Furthermore, PTPN14 was also certified to operate the translocation and phosphorylation of YAP. The present experiment was aimed to explore the impact of PTPN14 on gastric cancer (GC) cell proliferation and migration through regulating the phosphorylation of YAP.</p><h3> Methods</h3><p>The pEGFP‐N1‐PTPN14 recombinant plasmid was stably transfected into three differentiation degrees GC cell lines, including MKN‐28, SGC‐7901, and BGC‐823. Quantitative reverse transcription‐polymerase chain reaction and Western blot assay were performed to analyze the messenger RNA (mRNA) and protein levels. The proliferative and migratory capacity of cells was appraised by Cell Counting Kit‐8 assay and transwell chamber.</p><h3> Results</h3><p>Compared with the normal control and vector transfection group, the capacity of these three cell lines, which transfected with the pEGFP‐N1‐PTPN14 to proliferate and migrate in vitro was increased obviously (<i>P</i> YAP mRNA detected in MKN‐28 cell line. Meanwhile, after transfecting the pEGFP‐N1‐PTPN14 plasmid, the mRNA level of <i>YAP</i> in SGC‐7901 was reduced (<i>P</i> P P </p><h3> Conclusion</h3><p>PTPN14 could enhance the proliferative and migratory ability of GC cells by promoting the YAP phosphorylation in the Hippo signaling pathway. Taken together, PTPN14 might be involved in the occurrence and development of GC and become a molecular regulator to treat GC.</p>

cell biology,biochemistry & molecular biology

Laparoscopically assisted percutaneous endoscopic gastrostomy

YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression

YAP induces FAK phosphorylation to inhibit gastric cancer cell proliferation via upregulation of HMGB1

Significant association of YAP1 and HSPC111 proteins with poor prognosis in Chinese gastric cancer patients

YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes

Gli1 Interacts with YAP1 to Promote Tumorigenesis in Esophageal Squamous Cell Carcinoma.

Yes-associated Protein 1 Promotes Papillary Thyroid Cancer Cell Proliferation by Activating the ERK/MAPK Signaling Pathway

EphA2-to-YAP pathway drives gastric cancer growth and therapy resistance

Multi-day Adaptation and Savings in Manual and Locomotor Tasks

Yes-Associated Protein 1 (Yap) In The Growth And Tumorigenesis Of Ovarian Granulosa Cells.

LncRNA PVT1 Promotes Cell Proliferation, Invasion, and Migration and Inhibits Cell Apoptosis by Phosphorylating YAP

USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer

Expression of Yes-associated protein in gastric adenocarcinoma and its clinical significance

Overexpressed MAGP1 is Associated with a Poor Prognosis and Promotes Cell Migration and Invasion in Gastric Cancer

YAP is a Critical Oncogene in Human Cholangiocarcinoma

Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy

[Subgroup analysis results of platelet inhibition trial in acute coronary syndrome patients (PLATO) who underwent intervention or medical treatment].

PKP2 induced by YAP/TEAD4 promotes malignant progression of gastric cancer

m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1

YAP Regulates Cell Proliferation, Migration, and Steroidogenesis in Adult Granulosa Cell Tumors.

Nonreceptor tyrosine phosphatase 14 promotes proliferation and migration through regulating phosphorylation of YAP of Hippo signaling pathway in gastric cancer cells